Lyndra’s Series E Cash Expected To Get Weekly Risperidone To An FDA Filing

 
• By Joseph Haas

Working for years to develop weekly or monthly oral drugs, Lyndra raises $101m and licenses commercial rights in six nations to Sun Pharma in a deal getting its lead product closer to the finish line.

Money in sack on wooden table
Lyndra raises $101m in private equity cash while awaiting Phase III data

More from Strategy

More from Business